01 AUG 2018
FOR RELEASE: Brussels, BE and Raleigh, NC
BioPontis Alliance appoints new Chief Scientific Officer
BioPontis Alliance Rare Disease Foundation is pleased to announce the appointment of Gilbert W. Carnathan as Chief Scientific Officer following the retirement of Dr. David Spencer who now serves as a director on the BioPontis Alliance Foundation Board.
Dr. Gilbert (Chip) Carnathan, PhD, RAC is a career pharmaceutical executive with extensive experience in drug discovery and drug development. As a consultant he has collaborated with both start-up biotechnology and established pharmaceutical companies to design innovative and expeditious US and global drug development strategies. In addition, he represents these companies in their interactions with FDA. Prior to BioPontis, his most recent projects have been as an independent consultant; however, Chip has served in consulting roles as the President of Origin USA LLC, Senior Director of US Regulatory Affairs at SRA International and as Senior Director of Regulatory Affairs at Impact Pharmaceuticals. At these CROs, he was responsible for the development of US and International regulatory strategies, the management of sponsored regulatory programs, and the design of preclinical development programs. In addition to his extensive experience as a consultant, Chip served as the Vice President responsible for preclinical research and development efforts at three biotechnology companies: Cortech, Napro Biotherapeutics, and Argos Therapeutics. Chip’s international non-profit experience comes from his three years as the Director of the International AIDS Vaccine Initiative. He started his industrial career in drug discovery and development at GD Searle and the Rorer Group. During a career spanning more than 35 years, Chip has played a key role in advancing more than 25 drugs, biologics, and vaccines into clinical development in the US, Europe, and Africa. He earned his PhD in Reproductive Pharmacology at the University of Massachusetts, Amherst.
Chip will continue collaborative development on BioPontis’ current projects in Charcot Marie Tooth disease and Huntington’s disease with University of Antwerp/VIB and Massachusetts General Hospital, respectively.
Chip states, “I am excited about joining the Foundation at this time when the gap between basic research and the development of clinical candidates continues to block the advancement of promising science for many rare diseases. Since the existing collaborations involve innovative discovery science, I know we will need to identify equally innovative approaches to develop our clinical candidates. I am looking forward to working with our collaborators, management team, board, and our Scientific Advisory Committee and volunteers, to provide this innovation.”
Dr. Carnathan will be based in North Carolina, USA.
About BioPontis Alliance for Rare Diseases
BioPontis Alliance for Rare Diseases is a 501c(3) public charity in the US (North Carolina) and a foundation of public utility (fup/son) in Belgium (Brussels). Managed by an international Board and executive team, BioPontis partners with patient organizations and clinical researchers to bridge the gap between promising science and new medicines. BioPontis Alliance for Rare Diseases is being established as a global non-profit, inviting corporate, private and foundation philanthropic support. More information, including how contributions to support our programs and mission can be made, at http://biopontisalliance.org.
Erik Tambuyzer, Chairperson BioPontis Alliance for Rare Diseases
+32 475 61 57 11 (Brussels, Belgium)
Richard Basile, CEO BioPontis Alliance for Rare Diseases
+1 919 345 5386 (Raleigh, USA)